Merck is undervalued with strong growth, profitability, and credit strength despite CDMO challenges, offering compelling ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

Merck & Co., Inc. (NYSE:MRK) ranks among the best magic formula stocks to invest in. On July 10, UBS reiterated its Buy ...

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...

Merck is seeking ways to prepare for a significant upcoming patent cliff. The company has just announced another acquisition ...

In June 2025, the FDA approved KEYTRUDA for perioperative use in adults with resectable, locally advanced head and neck ...

Initiating Rapid Micro Biosystems at 'buy' with $4.60 fair value, driven by strong growth potential in automated microbial ...

For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...

The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Eckhardt served as head of legal, overseeing M&A, ventures, and finance at the DAX-listed healthcare company based in ...